Table 1.
Effect of concomitant combination of EGFR-TKI (TKI: tyrosine kinase inhibitor) and CXCR7 inhibitor on A549 cells based on the Chou and Talalay method.
| Combination Treatment | TKIs (µM) | CXCR7i (µM) | FA | CI | Effect |
|---|---|---|---|---|---|
| Afatinib + CXCR7i | 10 | 10 | 0.84 | 0.47 | Synergistic |
| Erlotinib + CXCR7i | 10 | 10 | 0.55 | 0.74 | Moderately Synergistic |
| Gefitinib + CXCR7i | 10 | 10 | 0.47 | >1.1 | Antagonistic |
FA represents the fraction of growth effect of drug-treated cells compared with control cells and CI represents the combination index. CI = 1: additivity; CI > 1: antagonism; CI < 1: synergism.